GATTO, MARIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.215
AS - Asia 3.116
EU - Europa 2.992
AF - Africa 826
SA - Sud America 649
OC - Oceania 93
Continente sconosciuto - Info sul continente non disponibili 42
Totale 14.933
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.726
SG - Singapore 1.189
IT - Italia 928
CN - Cina 574
NL - Olanda 440
BR - Brasile 432
HK - Hong Kong 348
DE - Germania 303
FI - Finlandia 157
VN - Vietnam 134
GB - Regno Unito 116
SE - Svezia 100
PL - Polonia 97
FR - Francia 89
RU - Federazione Russa 78
IN - India 69
IE - Irlanda 63
AT - Austria 45
KR - Corea 44
MX - Messico 42
EG - Egitto 41
JP - Giappone 40
TR - Turchia 40
AO - Angola 38
CA - Canada 36
IQ - Iraq 35
KE - Kenya 35
EC - Ecuador 32
ES - Italia 32
JO - Giordania 32
GH - Ghana 31
GT - Guatemala 31
DO - Repubblica Dominicana 30
NI - Nicaragua 30
UA - Ucraina 30
ZA - Sudafrica 30
ID - Indonesia 29
HU - Ungheria 28
IR - Iran 28
PE - Perù 28
SA - Arabia Saudita 28
AL - Albania 27
AR - Argentina 27
BG - Bulgaria 27
DZ - Algeria 27
GR - Grecia 27
KZ - Kazakistan 27
AZ - Azerbaigian 26
CI - Costa d'Avorio 26
HN - Honduras 26
IL - Israele 26
MK - Macedonia 26
PA - Panama 26
PR - Porto Rico 26
ET - Etiopia 25
GN - Guinea 25
NC - Nuova Caledonia 25
TH - Thailandia 25
TJ - Tagikistan 25
TT - Trinidad e Tobago 25
ZW - Zimbabwe 25
BY - Bielorussia 24
CY - Cipro 24
ME - Montenegro 24
PY - Paraguay 24
AE - Emirati Arabi Uniti 23
CM - Camerun 23
CV - Capo Verde 23
CZ - Repubblica Ceca 23
NE - Niger 23
SN - Senegal 23
SO - Somalia 23
TL - Timor Orientale 23
CG - Congo 22
CO - Colombia 22
IS - Islanda 22
KH - Cambogia 22
LC - Santa Lucia 22
RS - Serbia 22
YE - Yemen 22
BB - Barbados 21
DK - Danimarca 21
KG - Kirghizistan 21
LV - Lettonia 21
PK - Pakistan 21
PS - Palestinian Territory 21
RO - Romania 21
SK - Slovacchia (Repubblica Slovacca) 21
UZ - Uzbekistan 21
XK - ???statistics.table.value.countryCode.XK??? 21
AM - Armenia 20
CU - Cuba 20
GF - Guiana Francese 20
JM - Giamaica 20
NP - Nepal 20
TZ - Tanzania 20
UG - Uganda 20
YT - Mayotte 20
BE - Belgio 19
BF - Burkina Faso 19
Totale 14.019
Salva come PNG Salva come JPEG
Città #
Fairfield 1.102
Ashburn 757
Singapore 749
Woodbridge 556
Chandler 548
Houston 445
Seattle 378
Ann Arbor 372
Cambridge 341
Hong Kong 336
Wilmington 289
Beijing 175
Santa Clara 144
Boardman 136
Padova 115
Munich 109
San Diego 103
Los Angeles 97
Medford 80
Princeton 80
Des Moines 73
Helsinki 73
Bytom 65
Dublin 58
New York 54
Chicago 52
Hefei 51
Ho Chi Minh City 45
Nanjing 43
Buffalo 40
São Paulo 40
Milan 39
Luanda 33
Amman 31
Turku 31
Nairobi 30
Redondo Beach 30
Managua 29
Rome 28
Dong Ket 26
Salt Lake City 26
Conakry 25
Nuremberg 25
Abidjan 24
Baku 24
Harare 24
London 24
Noumea 24
Seoul 24
Vienna 24
Dakar 23
Dushanbe 23
Lima 23
Phnom Penh 22
Accra 21
Athens 21
Castries 21
Dili 21
Panama City 21
Podgorica 21
Praia 21
Tokyo 21
Warsaw 21
Addis Ababa 20
Bishkek 20
Falkenstein 20
Guatemala City 20
Hanoi 20
Kampala 20
Dearborn 19
Minsk 19
Bridgetown 18
Cairo 18
Djibouti 18
Falls Church 18
Montevideo 18
Naples 18
Niamey 18
Papeete 18
Pristina 18
Tashkent 18
Bologna 17
Cotonou 17
Havana 17
Kingstown 17
Nassau 17
Yerevan 17
Dallas 16
Riga 16
San José 16
Stockholm 16
Ulan Bator 16
Amsterdam 15
Libreville 15
Limassol 15
Rio de Janeiro 15
Bamako 14
Cayenne 14
Mamoudzou 14
Nouakchott 14
Totale 8.943
Salva come PNG Salva come JPEG
Nome #
ISEV2022 Abstract Book 878
Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus. 245
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study 237
Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active disease. 217
Advances in the Diagnosis and Classification of Systemic Lupus Erythematosus 212
Transcriptional network profile on synovial fluid T cells in psoriatic arthritis 206
PTX3, Anti-PTX3, and Anti-C1q Autoantibodies in Lupus Glomerulonephritis. 199
Early disease and low baseline damage predict response to belimumab in patients with systemic lupus erythematosus 198
Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission 194
SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients 192
MicroRNAs in idiopathic inflammatory myopathies: state-of-the-art and future perspectives 191
A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab--comments on article by Fredericks et al. 190
17-β-estradiol affects BLyS serum levels and the nephritogenic autoantibody network accelerating glomerulonephritis in NZB/WF1 mice. 190
Diagnostic and prognostic role of renal histopathology in rheumatic diseases 189
SERPINB3 delays glomerulonephritis and attenuates the lupus-like disease in lupus murine models by inducing a more tolerogenic immune phenotype 181
Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis 180
Overlap connective tissue disease syndromes. 179
The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients 178
Cardiovascular risk factors, burden of disease and preventive strategies in patients with systemic lupus erythematosus: A literature review 176
Anti-MDA5 dermatomyositis: an update from bench to bedside 173
Clinical Guidelines and Definitions of Autoinflammatory Diseases: Contrasts and Comparisons with Autoimmunity-a Comprehensive Review. 173
Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies 172
The clinical features, diagnosis and classification of dermatomyositis. 171
IL-12 and IL-23/Th17 axis in systemic lupus erythematosus 168
Immunization with pentraxin 3 (PTX3) leads to anti-PTX3 antibody production and delayed lupus-like nephritis in NZB/NZW F1 mice. 167
Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis 164
The olfactory function is impaired in patients with idiopathic inflammatory myopathies. 162
Lupus nephritis: clinical presentations and outcomes in the 21st century 161
Prolonged remission in Caucasian patients with SLE: prevalence and outcomes 159
New therapeutic strategies in systemic lupus erythematosus management 159
Belimumab: a step forward in the treatment of systemic lupus erythematosus 159
Remission in systemic lupus erythematosus: Testing different definitions in a large multicentre cohort 158
Predictors of maternal and fetal complications in SLE patients: a prospective study. 157
Emerging and critical issues in the pathogenesis of lupus. 155
Clinical and pathologic considerations of the qualitative and quantitative aspects of lupus nephritogenic autoantibodies: A comprehensive review 155
Correction to: Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies. 155
Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis 155
Rheumatic and autoimmune thyroid disorders: a causal or casual relationship? 153
Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: data from a large multicentric cohort 148
Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature. 148
Physician’s global assessment is often useful in SLE, but not always: the case of clinical remission 147
Premature coronary heart disease in SLE: can we prevent progression? 145
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort 143
Nephritogenic-antinephritogenic antibody network in lupus glomerulonephritis 142
Novel Pathogenic Pathways and Therapeutic Implications in Lupus Nephritis: The Emerging Role of PTX3-Related Immunity 142
Prevalence, outcome and management of patients with SLE and secondary antiphospholipid antibody syndrome after aPL seroconversion 140
The interferon in idiopathic inflammatory myopathies: Different signatures and new therapeutic perspectives. A literature review 138
Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up 135
Immunization with Pentraxin3 prevents transition from subclinical to clinical lupus nephritis in lupus-prone mice: insights from renal ultrastructural findings.   135
Optimizing outcome in SLE: treating-to-target and definition of treatment goals. 134
Circulating Pentraxin3-Specific B Cells Are Decreased in Lupus Nephritis 134
Assessment of disease activity and damage in SLE: Are we there yet? 134
Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission 131
Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis 130
Cytoarchitectureal changes in hippocampal subregions of the NZB/W F1 mouse model of lupus 128
Vaccination of mice for research purpose: alum is as effective as and safer than complete Freund adjuvant. 128
Human papillomavirus vaccine and systemic lupus erythematosus. 127
Autoantibody testing in patients with myositis: clinical accuracy of a multi parametric line immunoassay 127
Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management 126
Circulating extracellular vesicles and small non-coding RNAs cargo in idiopathic inflammatory myopathies reveal differences across myositis subsets 124
Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study 124
The body against self: autoinflammation and autoimmunity. 124
Unresolved and critical issues in autoimmune rheumatic diseases 120
Serpins, Immunity and Autoimmunity: Old Molecules, New Functions. 117
Controversies in Rheumatology and Autoimmunity: Approaching the truth by the discussion 117
Preclinical and early systemic lupus erythematosus 117
How I treat idiopathic patients with inflammatory myopathies in the clinical practice 116
Autophagy in human health and disease. 114
IgG anti-Pentraxin 3 antibodies are a novel biomarker of ANCA-associated vasculitis and better identify patients with eosinophilic granulomatosis with polyangiitis 114
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management 112
Rituximab-associated hypogammaglobulinaemia in ANCA-associated vasculitis and connective tissue diseases: a longitudinal observational study 112
Value and goals of treat-to-target in systemic lupus erythematosus: knowledge and foresight. 111
Galectin-3 in autoimmunity and autoimmune diseases 111
Role of galectin-3 in autoimmune and non-autoimmune nephropathies 111
Pulmonary involvement in antisynthetase syndrome 111
Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study 109
Lymphocyte immunophenotyping in inflammatory myositis: a review 109
Current clinical and therapeutic approach to tumour-like mass lesions in granulomatosis with polyangiitis 109
Nonimmune mechanisms in idiopathic inflammatory myopathies 107
What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts 107
The SLE-DAS provides an accurate and feasible flare tool in the clinical setting: a validation study 107
New onset and flare of rheumatic diseases following COVID-19 vaccination are mild and respond well to treatment: 9-month follow-up data from a single centre cohort 106
Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren’s syndrome: a literature review 105
Size-Exclusion Chromatography Combined with Ultrafiltration Efficiently Isolates Extracellular Vesicles from Human Blood Samples in Health and Disease 104
Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry 104
In-/off-label use of biologic therapy in systemic lupus erythematosus 101
The new targeted therapy in systemic lupus erythematosus: Is the glass half-full or half-empty? 101
Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis 98
Caveats and pitfalls in defining low disease activity in systemic lupus erythematosus 95
CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies 94
CHARACTERIZATION OF EXTRACELLULAR VESICLES SURFACE LYMPHOCYTES MARKERS AND MICRORNA CARGO IN PATIENTS AFFECTED WITH IDIOPATHIC INFLAMMATORY MYOPATHIES 93
Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases 91
Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies 90
The Management of Systemic Lupus Erythematosus (SLE) Patients in Remission 89
B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab 89
Defining the targets in SLE management: insights and unmet gaps 83
Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab 81
Evaluation of extracellular vesicles as potential biomarkers of myositis 79
Three years is the minimal effective duration of sustained clinical remission which prevents impaired kidney function and damage accrual in lupus nephritis 77
Evaluation of extracellular vesicles as potential myositis biomarkers 77
Totale 14.630
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.773
article - articoli 47.389
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 96.162
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021940 0 0 0 0 16 42 49 108 111 224 129 261
2021/20221.267 51 135 135 83 81 116 76 114 63 51 81 281
2022/20231.010 202 117 29 138 129 138 13 76 95 12 39 22
2023/2024763 27 74 88 67 63 104 60 47 44 24 79 86
2024/20253.457 13 185 119 143 320 108 674 450 222 137 455 631
2025/20264.899 599 839 1.499 1.874 88 0 0 0 0 0 0 0
Totale 15.109